Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin.

Antimicrobial Agents and Chemotherapy
R F MalacoffV T Andriole

Abstract

The pharmacokinetics of tobramycin and clindamycin were examined in patients undergoing peritoneal dialysis for chronic renal failure. Peak serum levels of tobramycin in functionally anephric patients were less than expected, probably secondary to a larger volume of distribution. Peritoneal dialysis resulted in a significant clearance of tobramycin, with a resultant reduction in serum half-life. The present data suggest that, if bactericidal serum levels of tobramycin are to be maintained in patients undergoing peritoneal dialysis, a parenteral loading dose be administered, followed by either (i) an identical dose every third half-life or (ii) one-half the loading dose every half-life. However, optimal therapy is best achieved by monitoring serum levels to insure appropriate drug dosage. Peak serum levels of clindamycin in functionally anephric patients were approximately twofold greater than those expected in normals after an identical parenteral dose. It is, therefore, recommended that the administered dose of this agent in functionally anephric patients be one-half of that required to produce desired peak serum levels in patients without renal impairment. Peritoneal clearance of clindamycin during dialysis was shown to be es...Continue Reading

References

Apr 1, 1973·Antimicrobial Agents and Chemotherapy·V K SimonV Malerczy
Jun 20, 1970·British Medical Journal·A M GeddesG J Grimshaw
May 1, 1973·Journal of Clinical Pharmacology·R M DeHaanW D Vandenbosch
Feb 1, 1974·Journal of Clinical Pharmacology·A M Joshi, R M Stein
Sep 1, 1973·Antimicrobial Agents and Chemotherapy·R C GordonW M Kirby
Jan 1, 1973·Antimicrobial Agents and Chemotherapy·W R Lockwood, J D Bower
Jun 1, 1973·Kidney International·R C AtkinsH Mion
Oct 1, 1973·Antimicrobial Agents and Chemotherapy·A J WeinsteinR C Moellering
Dec 1, 1971·The Journal of Infectious Diseases·R E WintersW L Hewitt
Feb 21, 1972·JAMA : the Journal of the American Medical Association·R E CutlerA W Forrey
Dec 1, 1971·The Journal of Infectious Diseases·A M GyselynckR Cutler
Dec 1, 1971·The Journal of Infectious Diseases·T SmithivasJ J Rahal
Dec 1, 1971·The Journal of Infectious Diseases·L J Riff, G G Jackson
Jul 1, 1968·The American Journal of the Medical Sciences·J G WagnerW L Lummis
Jun 1, 1969·The Journal of Clinical Investigation·L W Henderson, K D Nolph

❮ Previous
Next ❯

Citations

Jan 1, 1997·Seminars in Dialysis·E F Foote, L Avery
Sep 1, 1976·Antimicrobial Agents and Chemotherapy·M J AhernV T Andriole
Feb 1, 1977·Antimicrobial Agents and Chemotherapy·L RegeurJ P Kampmann
Feb 1, 1988·Antimicrobial Agents and Chemotherapy·R L DavisA N Smith
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Nov 1, 1981·Drug Intelligence & Clinical Pharmacy·W S Burkle
Oct 1, 1984·Orthopedics·G H Karam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.